Trial · NCT04102800
Benralizumab Exacerbation Study
NCT04102800, Phase 4, Completed, NHS Greater Glasgow and Clyde
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Benralizumab Exacerbation Study. Trials, record NCT04102800. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04102800
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Benralizumab Exacerbation Study
- NCT number
- NCT04102800
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 157 participants, actual
- Lead sponsor
- NHS Greater Glasgow and Clyde
- Conditions
- Asthma
- Interventions
- Benralizumab
- First posted
- 2019-09-25
- Last updated
- 2024-04-25
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Blood eosinophil counts during a clinical deterioration whilst on benralizumab | up to 56 or 80 weeks | |
| Primary | Fall in lung function, as measured by FEV1, during a clinical deterioration whilst on benralizumab. | up to 56 or 80 weeks | |
| Primary | Change in asthma symptom scores during a clinical deterioration whilst on benralizumab. | up to 56 or 80 weeks | |
| Primary | The number of patients progressing to rescue oral corticosteroids during a clinical deterioration whilst on benralizumab. | up to 56 or 80 weeks | |
| Secondary | Measurement of the magnitude of response to benralizumab - oral steroid reduction with benralizumab at 56 weeks | 56 weeks | proportion of patients who reduce high dose steroid courses and/or maintenance steroid dose by \>=25%, 50%, 75% and 100% |
| Secondary | Measurement of the magnitude of response to benralizumab - numbers of participants with and early and final good response | 16, 24 weeks, 1 year | Early (16/24 weeks): A GETE response of 'good' or 'excellent' to treatment with benralizumab as determined by the study physician. Final (one year): defined as a reduction of high dose corticosteroid courses by \>=50% compared to the previous year and/or reduction of maintenance oral steroid dose by \>=50% |
| Secondary | Measurement of the magnitude of response to benralizumab - inflammatory markers at 16 and 56 weeks compared to baseline | 16, 56 weeks | FBC to include Blood eosinophils, sputum eosinophils, blood neutrophil counts |
| Secondary | Measurement of the magnitude of response to benralizumab - inflammatory markers at 16 and 56 weeks compared to baseline | 16, 56 weeks | Measurement of exhaled nitric oxide |
| Secondary | Measurement of the magnitude of response to benralizumab - change in lung function, as measured by FEV1, at 16, 24 and 56 weeks compared to baseline | 16, 24 and 56 weeks | FEV1 post salbutamol on spirometry and FEV1 in daily diary |
| Secondary | Measurement of the magnitude of response to benralizumab - change in lung function at 16, 24 and 56 weeks compared to baseline | 16, 24 and 56 weeks | peak expiratory flow from the daily electronic meter |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33369570 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04102800
GET https://conductscience.org/api/trials/v1/NCT04102800/registered